AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

PCT LTD Announces New Purchase Order as the Result of a Successful Trial of Annihilyzer® Infection Control Systems

May 6, 2019

LITTLE RIVER, S.C., May 06, 2019 (GLOBE NEWSWIRE) -- PCT LTD (OTC Pink: PCTL), through its operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp), announced today that ACE Janitorial Supply Company (“ACE”), PCT Corp.’s distributor for the New York hospital and healthcare market, received a new purchase order for Morgan Stanley Presbyterian Children’s Hospital to continue using PCT Corp.’s patented Annihilyzer® Infection Control System following a successful 60-day trial within the facility. Morgan Stanley Presbyterian Children’s Hospital is the fourth hospital to become a customer of PCT Corp’s. and to take a proactive approach in providing patients, visitors and staff a new type and level of protection from the potential of hospital-associated infections.

The Annihilyzer® Infection Control System produces on-site generated Electro-Chemically Activated (“ECA”) cleaning and disinfectant fluid solutions that allow hospitals to move away from traditional disinfectants that are toxic and can cause harm to the people, equipment and furnishings that are exposed to them. The Annihilyzer® Infection Control System produces a hospital-level disinfectant fluid solution that is effective against hospital-acquired infections (HAI’s) like MRSA, VRE and C-diff, yet these fluid solutions pose none of the threats of the previously-used disinfecting chemicals. The system also includes a patented RFID material tracking system that not only tracks the life cycle of the disinfectant, but also supplies hospital administrators with valuable data about who performed sanitation services, when and where those services were provided, and confirms that the disinfection process protocols were followed.

PCT Corp.’s healthcare sales professionals are currently working with “ACE” to finalize the scheduling of the next two proactive hospitals in the Greater New York area for 60-day trials of PCT’s Annihilyzer Infection Control System.

About PCT LTD (“PCTL”) focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting and tracking technologies products. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC, “PCTL” aspires to and is actively engaged in preparations for up-listing its common stock to a national securities exchange. The Company established entry into its target markets with commercially-viable products and now continues to gain market share.

Forward-Looking Statements

This press release contains “forward-looking statements” as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements.” Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: any implied or perceived benefits resulting from the continued positive results relating to the installation of PCT’s Annihilyzer® systems in hospitals; the results of any manufacturers’ representative and/or license agreements, actual sales revenue to be derived from agreements, if any such contract is executed; PCT LTD’s and its subsidiary’s business prospects; PCT LTD’s ability to raise sufficient funds to satisfy its working capital requirements; the ability of PCT LTD to execute its business plan or list its common stock on a national stock exchange; benefits of the Annihilyzer® Infection Control Systems, Hydrolyte® generators and fluids; any other effects resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements PCT LTD makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the United States Securities Exchange Commission. PCT LTD undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:

Gary Grieco, Chairman of the Board (843) 390-7900 Office (843) 390-2347 Fax www.para-con.comwww.pcthealth.comwww.survivalyte.com

Brokers and Analysts: Chesapeake Group (410) 825-3930 info@chesapeakegp.com